Biomedcode’s R&D department develops novel preclinical platforms following a standardized pipeline.
This pipeline starts with the generation of genetically modified mice or the development of an appropriate induced mouse model in wild type mice or mice with humanized drugable targets.
The newly generated mouse model is further phenotyped to identify similarities to human pathologies while in vivo, ex vivo and histopathological readouts combined with molecular and cellular assays are established to allow the evaluation of the severity of the pathology.
Combining the above in standardized protocols validated with human therapeutics for the establishment of the optimal therapeutic window leads to the generation of preclinical platforms that offer:
Close correlation to human pathology
Humanized drugable targets
Optimal therapeutic window and high sensitivity